Novartis AG

NVS Stock Report Card

Today's performance

66%

Performance

Score:

100/100

NVS returned 18.42% in the last 12 months. Based on SPY's performance of -7.16%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

Score:

67/100

3 analysts offer 12-month price targets for NVS. Together, they have an average target of 0, the most optimistic target put NVS at 0 within 12-months and the most pessimistic has NVS at 0. These analyst ratings are from our partners at Financial Modeling Prep (https://site.financialmodelingprep.com/) and Alpha Vantage (https://www.alphavantage.co/).

Technicals

Score:

79/100

NVS receives a 78 of 100 based on 14 indicators. 10 are bullish, 2 are bearish.

Earnings

Score:

36/100

NVS has missed earnings 4 times in the last 20 quarters.

Profit

Score:

71/100

Out of the last 20 quarters, NVS has had 20 profitable quarters and has increased their profits year over year on 8 of them.

Volatility

Score:

48/100

NVS has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

Novartis AG Summary

New York Stock Exchange / NVS

Healthcare

Drug Manufacturers—General

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Pluto is a technology provider that provides you with information, software, and automation tools for the purpose of investment education, but it does not make investment recommendations of securities, investment strategies, or account types, either in general or individualized for you or any other subscriber. If you want to receive individualized investment advice, you should consult with your own financial adviser. Pluto also does not provide you with legal, tax, or accounting advice. You agree that you understand that Pluto is not an investment adviser or a broker-dealer and does not have a fiduciary duty to you or a duty to act in your best interests. Pluto can help you back-test the historical performance of strategies that you create, but it does not recommend strategies and reminds you that the historical performance of a strategy is not a reliable predictor of future results for that strategy. Pluto uses third-party information, for example, about securities market data, that it reasonably believes to be reliable, but it does not warrant that the information is complete, accurate, or up-to-date, and as discussed further below, Pluto does not provide any warranty of merchantability or warranty for a particular purpose for that third-party market data or other information. Investing involves risk, including the risk of loss, and you should not use the Pluto technology in connection with investments unless you are able to and intend to evaluate the technology and the risks and make your own self-directed investment decisions.

Power up your portfolio

Build a portfolio of your favorite stocks

Pluto makes it easy to build investing strategies and automate your portfolio

See how

Checkout Similar Companies

NVS scored highly on our reportcard. Here are some similar companies and how they performed.

Johnson & Johnson

$JNJ Stock Report Card

Eli Lilly & Co.

$LLY Stock Report Card

Pfizer Inc.

$PFE Stock Report Card

UNITEDHEALTH GROUP INCORPORATED (Delaware)

$UNH Stock Report Card

Novo-Nordisk A/S

$NVO Stock Report Card

Merck & Co., Inc.

$MRK Stock Report Card

ABBVIE INC.

$ABBV Stock Report Card

AstraZeneca PLC

$AZN Stock Report Card

View all stock report cards

Los Angeles, CA

Pluto is not a broker-dealer, investment adviser or member of FINRA. Securities offered by Alpaca Securities LLC (“Alpaca Securities”). Alpaca Securities is a member of FINRA and the Securities Investor Protection Corporation.

Alpaca Securities, LLC (“Alpaca Securities”) is not responsible for and is not providing the technology and services you receive from us to access and manage your brokerage account with Alpaca Securities. You firmly agree to hold Alpaca and its affiliates, owners, directors, employees, clearing firm and agents harmless for any loss or damage arising from the use of or unavailability of the technology and services that we are providing.

The content on this website is for informational purposes only. Pluto does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing.